US EditionScotiabank Initiates Coverage on Arcturus Therapeutics (ARCT)
Summary by Stockxpo - A Professional Network of Traders, Investors and Analysts
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Scotiabank Initiates Coverage on Arcturus Therapeutics (ARCT)
On May 28, 2025, Arcturus Therapeutics (ARCT, Financial) received a new analyst rating from Scotiabank. The coverage was initiated by analyst Greg Harrison who assigned a “Sector Outperform” rating to the stock. This marks the first time Scotiabank has provided a rating for Arcturus Therapeutics. Scotiabank has announced a price target of $32.00 USD for Arcturus Therapeutics (ARCT, Financial). It is important to note that there is no prior price…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
